Targeting STAT3 not only disrupts this chemoresistance mechanism but also reduces growth and clonogenicity in tumor-derived organoid models, emphasizing the potential of inhibiting this pathway to overcome Treg-mediated chemoresistance in tumor settings [74]. This evidence concerns the gene STAT3 and neoplasm.